Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Arcellx, Inc. (ACLX)
Company Research
Source: Business Wire
– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma –– FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma –– Provides Gilead with Full Control of Anito-cel, Accelerating Development and Commercialization while Eliminating Profit-Share, Milestones, and Royalties – FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.This press release features multimedia. View the full release here: https://www.business
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance]Yahoo! Finance
- Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more [CNBC]CNBC
- ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its ShareholdersBusiness Wire
- Gilead to acquire Arcellx for $7.8 billion [Yahoo! Finance]Yahoo! Finance
- Assessing Arcellx (ACLX) Valuation After New Anito Cel Safety Data And Shifting Analyst Views [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 2/23/26 - Form SCHEDULE
- 2/23/26 - Form SC
- 2/19/26 - Form 144
- ACLX's page on the SEC website